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Summary
JM-216 is an orally bioavailable platinum compound with activity against many tumor models. The objective of this
study was to determine the safety profile and anti-tumor activity of JM-216 in patients with hormone refractory prostate
cancer (HRPC) when given orally daily × 5 days. In this open label phase II study JM-216 was administered orally
at the dose of 120 mg/m2/d for 5 days every 4 weeks. Patients continued on the therapy until evidence of disease
progression or intolerable toxicity developed. Dose escalation and de-escalation were allowed according to patient’s
tolerance. Thirty-nine patients were enrolled onto the study and received a total of 155 courses (median 2, range 1–16)
of JM-216. Dose delays (77% of courses) and dose reductions (31% of courses) were common and were mainly due
to myelosupression. Treatment was discontinued in 5 patients due to treatment related toxicities. One patient developed
myelodysplastic syndrome 11 months after the start of treatment. The most frequent grade III or higher adverse events
included thrombocytopenia (54%), neutropenia (52%), anemia (24%) nausea (13%), vomiting (16%) and diarrhea (28%).
PSA response was assessed in 32 patients, 10 (26%) had partial response, 14 (36%) had stable disease while PSA
progression was seen in 8 (21%) patients. Of 20 (54%) patients with measurable disease two patients had a documented
partial response. Although JM-216 had moderate activity in HRPC when given on daily basis for 5 days, it is associated
with significant treatment related toxicities in this patient population.
Introduction
Metastatic prostate cancer remains the second leading
cause of male cancer deaths in the United States of Amer-
ica with estimated 28, 900 deaths in the year 2003 [1].
Although androgen deprivation is the mainstay of treat-
ment in metastatic prostate cancer it is generally consid-
ered palliative and all patients eventually become resis-
tant to hormonal therapy. Once prostate cancer becomes
hormone refractory, the prognosis is dismal with a me-
dian overall survival generally demonstrated to be less
than one year [2]. To date none of the several clinical
trails evaluating experimental chemotherapeutic and or
hormonal regimens in hormone refractory prostate can-
cer (HRPC) patients had demonstrated a definite survival
benefit [2]. Due to the use of differing response and entry
criteria the comparison of objective advantage obtained
from the use of these cytotoxic agents is difficult to assess
[3, 4]. Nonetheless objective response rate (i.e. reduc-
tion in measurable disease including complete and partial
response) remains less than 10% with most of these reg-
imens [5]. Although no evidence was available in favor
of chemotherapy improving the survival in HRPC recent
trials have demonstrated encouraging results in symptom
palliation, response rate and quality of life [6].
JM-216, (BMS-182751, Satraplatin), {bis (aceto) am-
mine dichloro (cyclohexamine) platinum (IV)}, is a novel
platinum analog that can be administered orally on a daily
basis [7]. JM-216 has shown antitumor activity compara-
ble to that of cisplatin or carboplatin in human ovarian
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carcinoma xenograft and murine sarcoma models [8]. It
has also shown antitumor selectivity far superior to that
observed for cisplatin or carboplatin against murine plas-
macytoma in the in vivo preclinical studies [9]. Although
phase I studies of JM-216 as a single agent have evalu-
ated three administration schedules, daily dose for 5 con-
secutive days, every three weeks was the recommended
schedule for further studies due to ease of administration
and best tolerability [10]. Utilizing this schedule the dose-
limiting toxicities included thrombocytopenia, and diar-
rhea and the maximum tolerated dose (MTD) was 100–
140 mg/m2/d. The most frequent reasons for treatment
discontinuations due to an adverse effect were hemato-
logic and/or gastrointestinal toxicities. The recommended
phase II dose using the daily times 5 days schedule was
100–120 mg/m2/d every three to four weeks [10, 11]. Mul-
tiple phase I/II trials have evaluated the role of cisplatin
and carboplatin, either as single agent or in combination
with other cytotoxic agents, in HRPC [12–18]. The ob-
jective response rate to single agent cisplatin ranged 0 to
19% in these trials and was comparable to that seen with
other chemotherapeutic agents in HRPC [14–18]. Car-
boplatin in combination with pactlitaxel and estramustine
phosphate (TEC) has shown significant antitumor activity
(45% response rate in patients with measurable disease)
[12, 13]. Based on these results, ease of daily oral admin-
istration and the need for improved therapy for HRPC a
phase II study of JM-216 in the treatment of HRPC was
undertaken. The objectives of the study were to deter-
mine the anti-tumor activity of JM-216 in the treatment
of HRPC, and to evaluate the safety profile of this unique
agent in this patient population and schedule proposed.
Patients and methods
Patient eligibility and evaluation
From December 1995 to October 1998 patients with histo-
logically confirmed metastatic prostatic adenocarcinoma,
who had disease progression despite one or more hor-
monal therapies, and after anti-androgen withdrawal were
enrolled in the study. Both measurable and evaluable pa-
tients were eligible for the study provided progression of
disease could be objectively established. Progression was
demonstrated by worsening disease on bone scan or other
objective measures including bone X-ray, CAT scan and
magnetic resonance imaging (MRI). Isolated increase in
Prostate Specific Antigen (PSA) was not considered suf-
ficient evidence of disease progression. Patients were re-
quired to have ECOG performance status of 0–2, and a
life expectancy of at least 6 months. No prior cytotoxic
chemotherapy (including suramin) or large field radiation
(greater than 30% of marrow bearing area) was allowed.
Patients were required to have adequate bone marrow re-
serve, renal and hepatic function. Sexually active, fertile
patients were required to use effective birth control meth-
ods while receiving study drug. Individuals were excluded
if they were diagnosed with a serious concurrent uncon-
trolled medical disorder; a history of major gastrointesti-
nal surgery or pathology likely to influence absorption;
and a history or prior malignancy except appropriately
treated localized epithelial skin cancer.
Pretreatment evaluation included a history and physical
examination including height, weight, performance sta-
tus, and symptom review. Pretreatment testing included
an EKG, chest X-ray, pain assessment, and tumor assess-
ment. Laboratory tests required within 14 days of initial
treatment included the following: complete blood count
(CBC), blood chemistry profile, urinalysis, PSA and cre-
atinine clearance in case of abnormal serum creatinine.
While receiving treatment, weekly CBC was obtained.
History and physical examination, pain assessment, blood
chemistry profile, urinalysis and PSA were required prior
to each treatment cycle. Repeat creatinine clearance val-
ues were obtained if the serum creatinine rose to above
the upper normal limit. Chest X-ray and EKG were re-
peated as clinically indicated. Toxicity assessment was
performed at every clinic visit using National Cancer In-
stitute common toxicity criteria (version 1). Tumor re-
assessment was required prior to every other course and
as clinically indicated.
Treatment
JM-216 was provided by Bristol-Myers Squibb Pharma-
ceutical Research Institute in capsules of 10 mg, 50 mg,
and 200 mg. JM-216 was initiated at 120 mg/m2/d for five
days, repeated every three weeks. The dose interval was
amended to every four weeks after the first five patients
experienced delayed hematologic recovery. Dose escala-
tion or de-escalation was allowed according to preplanned
dose adjustment schema that is shown in Table 1. Patients
were allowed to continue treatment as long as clinical
benefit was observed, in the absence of disease progres-
sion and/or intolerable toxicities. Reasons for termination
Table 1. Schema for planned dose adjustments
Toxicity Dose adjustmenta
≤Grade 1 hematological toxicityb Escalate to next level
Equal to grade II hematological toxicity No change
≥Grade II hematological toxicity Reduce one level
or 25–50% reduction in creatinine clearance
aDose levels: − 2 = 80 mg/m2/d, − 1 = 100 mg/m2/d,0 = 120 mg/m2/d,
+ 1 = 140 mg/m2/d, + 2 = Do not exceed 140 mg/m2/d.
bAccording to CTC version 1.
81
included toxicity, disease progression, patient request,
non-compliance, or physician decision.
Evaluation
Evaluation for progression of disease or response to
chemotherapy was performed using physical examina-
tion, bone scans, bone X-rays, and other appropriate imag-
ing techniques and PSA levels. Measurable disease was
defined as lesions measurable in two perpendicular diam-
eters. A complete response (CR) in patients with measur-
able disease consisted of complete disappearance of all
tumor lesions and of all signs and symptoms of disease
for at least four weeks from the date of documentation
of the complete response. A partial response (PR) among
patients with measurable disease consisted of a decrease
by more than 50% in the sum of the products of the two
largest perpendicular diameters of all measurable lesions
as determined by two consecutive observations, at least
four weeks apart. Stable disease was defined as failure to
observe either a CR or PR, in the absence of progressive
disease (PD), as determined by two consecutive observa-
tions at least four weeks apart. Progressive disease was
determined by an increase in size by at least 25% of any
measurable or evaluable lesion, and/or the appearance of
new lesions or the occurrence of malignant pleural effu-
sion or ascites.
A complete PSA response was defined as PSA values
within institutional normal range provided there was no
disease progression during or before the response period.
Partial PSA response consisted of PSA values that had
decreased by at least 50% of their baseline values, without
disease progression during or before the response period.
A stable PSA response was defined as PSA values that are
less than 50% from the baseline value, provided there is no
CR, PR or PD, during or before the response period. PSA
progression was determined by PSA values with atleast
a 50% increase from the nadir value. Assessment of PSA
response required two consecutive PSA values at least
28 days apart for each of the circumstances (CR, PR, and
PD)
Statistical methods
The original study incorporated a two-stage accrual de-
sign to allow early termination should preliminary results
indicates that treatment has minimal activity or unaccept-
able toxicity in this population. Objective response rate
was the primary endpoint of the study. However, the de-
cision to continue the trial was based on overall evidence
of response including both objective response and PSA
response. Fifteen evaluable patients were to enter into
the study initially; if 2–4 responses were observed, then
stage two would begin with the accrual of 15 additional
patients to estimate the effectiveness of JM-216 in this pa-
tient population. If more than 7 responses were observed,
the regimen was concluded to be promising. Tabulations
and descriptive statistics were used to analyze patient
characteristics, drug efficacy, drug safety and laboratory
observations.
Results
The pretreatment characteristics of patients entered into
this trial are listed in Table 1. Thirty-nine patients were
registered from December 1995 to October 1998. All pa-
tients initiated treatment at a dose of 120 mg/m2/day and
received a total of 155 courses of JM-216 (median 2, range
1–16). The original protocol required that the chemother-
apy be given for five consecutive days every 21 days.
The protocol was amended in July 1996, to reflect the
discovery of late hematologic nadirs occurring at approx-
imately day 21 of each course. The cycle length was then
changed to every 28 days. Dose delays were common
and occurred in 88 (77%) of 116 courses delivered sub-
sequent to the first course and the median number of days
between courses was 38 (range 21–72 days). The ma-
jority of courses were delayed due to the late recovery
from hematologic toxicity. Dose reductions occurred fre-
quently and reasons for dose reduction included cytopenia
in 23 patients and an increase in creatinine in 2 patients. Of
37 patients who received a minimum of two courses, 22
(59%) patients required at least one dose reduction during
their treatment. Dose reductions occurred in 36 (31%) of
116 courses administered subsequent to the first course.
However, 10 (26%) patients who received a minimum
of two courses, were dose escalated to 140 mg/m2/day
at some point in time during their therapy. Permanent
dose discontinuation occurred in 5 patients. Three had el-
evated liver function tests and one each had leukopenia
and thrombocytopenia.
Hematologic toxicities are summarized in Table 2. Me-
dian time to hematologic nadir during evaluation of all
courses was day 27 for hemoglobin (range 2–154); day 22
for absolute neutrophil count (range 2–45) and day 24 for
platelet count (range 2–108). Fourteen patients required
transfusions for anemia or thrombocytopenia at some time
during their course of treatment. Approximately 88% of
patients had abnormal lymphocyte values at the initia-
tion of the study with 95% of patients developing grade 3
lymphopenia during the treatment phase. One patient de-
veloped a latent myelodysplastic syndrome (MDS) with
complex karyotype (including 7q-) on cytogenetic analy-
sis approximately eleven months after his treatment.
Non-hematological toxicities were mostly grade I or
II and included nausea (95%), asthenia (90%), diarrhea
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(87%), anorexia (69%), vomiting (51%) constipation
(44%), chills (38%), myalgia (36%), dysgeusia (33%),
dizziness (33%), and headache (31%). As summarized in
Table 2 Gastrointestinal toxicities were significant, with
Grade 3 or higher nausea, vomiting and diarrhea noted
in 13, 16 and 28% of the patients respectively. Approxi-
mately one-third of patients had an elevation of ALT, AST,
or total bilirubin from baseline at some point during treat-
ment. Most elevations were grade 1or II, transient, tended
to occur soon after the course of treatment and recurred
in some cases upon re-challenge with JM-216. Grade 3
or higher abnormalities of liver related enzymes occurred
in 4 patients and treatment was discontinued in three pa-
tients. Abnormalities of liver enzymes were uniformly re-
versible in all cases on discontinuation of therapy. Renal
toxicities were mild and infrequent with only two patients
requiring dose delays and reductions secondary to renal
function abnormalities. Seventeen patients reported a to-
tal of 35 hospitalizations during the course of this study.
Twelve of these hospitalizations were believed related to
study drug toxicity. Treatment were discontinued due to
progressive disease in 19 (49%) patients, treatment related
toxicity in 13 (33%) patients and upon patient’s request
in 5 (13%) cases.
Twenty patients (54%) had measurable disease. Two
patients, one with liver metastasis had a documented par-
tial response. The remaining 18 patients did not have any
measurable response to treatment, in 7 patients the disease
Table 3. Grade 3 or higher toxicities according to
CTC version 1











Elevated Liver enzymes 10
Renal 0
remained stable for the duration of treatment. PSA values
were measured at the time of each chemotherapy admin-
istration. Thirty-two patients had all PSA values available
for response assessment. A complete PSA response or a
partial PSA response was measured in 10 (26%) patients,
stable disease was noted in 14 (36%) patients while PSA
progression occurred in 8 (20%) patients. PSA response
could not be evaluated in 7 (18%) patients due to the miss-
ing values. Treatment was discontinued in many patients
before the documentation of PSA progression due to tox-
icity and other reasons, 14 (35%) patients enrolled in the
study had documented PSA progression during the treat-
ment period. The median survival for the whole cohort is
16.7 months (95% confidence interval 9.3–19.2 months).
The median PSA response duration was 3.8 months while
median progression-free survival was 7.7 months in 32 as-
sessable patients.
Discussion
JM-216 (BMS-182751, Satraplatin) is a novel orally
bioavalible platinum analog that had demonstrated anti-
tumor activity comparable with parentrally administered
cisplatin or carboplatin in both in vitro and in vivo stud-
ies. Although phase II studies in small cell lung cancer
JM-216 has shown considerable promise as first line ther-
apy [19], its antitumor activity in refractory cervical and
non-small cell lung cancers is at best modest [20, 21].
Its role as a radiation sensitizer and in combination with
other drugs has been evaluated in small studies [22, 23].
The overall response rate including objective and PSA re-
sponse (excluding stable disease) was 26% in this study.
Stable disease was observed in another 36% of the patients
demonstrating modest anti-tumor activity of JM-216 in
HRPC comparable to that observed for other cytotoxic
agents in this setting.
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Despite JM-216 showing modest activity within this
patient group, frequent dose modification and delays sec-
ondary to treatment-related toxicity complicated man-
agement considerably. The most common and signifi-
cant grade 3 or higher toxicities were myelosupression
(54%) and gastrointestinal (28%) as noted in previous
studies. The unexpected finding noted in this study was
the unusually late recovery of neutropenia and thrombo-
cytopenia as reflected by prolonged cycle interval (me-
dian 38 days) between subsequent courses. This result
could be explained partly by older age of the patients
and the fact that 61% of patients had received prior radi-
ation therapy that can potentially damage bone marrow
reserves [24]. It is more likely that the late nadir repre-
sents toxicity to stem cells, which has become evident
in this patient population. Development of MDS in one
patient eleven months after the therapy, the first noted
case of possible treatment related leukemia following JM-
216 therapy, supports the hypothesis of stem cell damage.
Presence of complex karyotype (including 7q-, an abnor-
mality typically associated with prior chemotherapy re-
lated leukemia/MDS) in our patient and existence of re-
ports describing higher incidence of secondary leukemia
following cisplatin and carboplatin therapy in ovarian
cancer favors this conclusion [25, 26]. The cause and
significance of lymphopenia in majority of patients dur-
ing the treatment phase is also not clear even though
it has been reported in other studies evaluating estro-
gen, corticosteroids, suramin and mitoxantrone in HRPC
[27–29].
Non hematological toxicities were mainly gastroin-
testinal with grade 3 or higher nausea, vomiting and diar-
rhea occurring in 13–28% of patients. Three patients were
hospitalized due to refractory gastrointestinal toxicities.
Elevation of the liver enzymes and bilirubin was noted
in approximately one third of the patients treated with
JM-216 at some point during their treatment. Although
these abnormalities were mild and transient in majority
of patients, contrary to previous studies treatment had to
be discontinued in three patients a finding that could also
be related to older age and higher dose of JM-216 in our
patients.
In conclusion although this study had demonstrated
a modest antitumor activity of JM-216, comparable to
other currently available chemotherapeutic agents for
HRPC, we believe that toxicities associated with this
dose and schedule significantly complicate the manage-
ment of these patients. As evident by frequent dose
delays and dose reductions starting dose in this trial
seems to be too high for prostate cancer patients. Fu-
ture studies should design to evaluate lower starting doses
with longer cycle duration especially if used in com-
bination with any other myelotoxic chemotherapeutic
agents.
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